Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Pulse Raises $100 Million for Imaging Diagnostics of Coronary Artery Disease

publication date: Aug 18, 2021

Pulse Medical Imaging Technology (Shanghai) completed a Series C financing of over $100 million for its imaging-based diagnoses of coronary artery disease. The company's products offer fast computation of fractional flow reserve (FFR) from multiple imaging data. Its angiography-based approach and intracoronary OCT-based approach (OFR) are precise, affordable tools for FFR in interventional cardiology. Pulse has formed a research partnership with Shanghai Jiao Tong University. The C round was co-led by existing investor GL Ventures, a Hillhouse company, along with Philips, Goldman Sachs and Boyu Capital. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China